
A new COVID subvariant spreads rapidly as Trump pivots away from vaccines
A new, highly transmissible COVID subvariant has been detected in California — heightening the risk of a potential summer wave as recent moves by the Trump administration threaten to make vaccines harder to get, and more expensive, for many Americans, some health experts warn.
Health and Human Services Secretary Robert F. Kennedy Jr. announced this week that he was rescinding the federal government's recommendation that pregnant women and healthy children get immunized against COVID, effective immediately.
Dr. Marty Makary, commissioner of the U.S. Food and Drug Administration, also said the agency will no longer routinely approve annually formulated COVID-19 vaccinations for healthy people under age 65.
'We simply don't know whether a healthy 52-year-old woman with a normal BMI who has had COVID-19 three times and has received six previous doses of a COVID-19 vaccine will benefit from the seventh dose,' Makary, along with another FDA official, Dr. Vinay Prasad, wrote in the New England Journal of Medicine this month. 'This policy will compel much-needed evidence generation.'
However, some experts say mandating more extensive testing could delay vaccine access for many, as those efforts may not even be complete until after the end of the upcoming winter flu-and-COVID season.
'Pregnant women, infants and young children are at higher risk of hospitalization from COVID, and the safety of the COVID vaccine has been widely demonstrated,' Dr. Sean O'Leary, chair of the American Academy of Pediatrics' Committee on Infectious Diseases, said in a statement.
The U.S. Centers for Disease Control and Prevention has said that, in general, getting an updated vaccine provides children and adults additional protection from COVID-related emergency room and urgent care visits.
The recent federal changes, according to some experts, could also prompt private insurance companies and government insurers to stop paying for COVID shots for wide segments of the population, including babies and children.
Absent a recommendation by federal officials, Americans could end up paying the entire cost of a vaccine, experts say. The out-of-pocket cost for a COVID vaccine at CVS, for instance, is $198.99.
Although the emergency phase of the pandemic has long since passed, authorities note COVID remains a public health concern. A relatively new subvariant has been spreading in Europe and Asia, 'particularly Hong Kong, Taiwan, other countries, Japan, etc.,' said Dr. Peter Chin-Hong, a UC San Francisco infectious diseases expert.
That subvariant, NB.1.8.1, was first documented in January and has since been detected in California, including in Los Angeles County and the San Francisco Bay Area. The World Health Organization designated it a 'Variant Under Monitoring' last week.
NB.1.8.1 has grown exponentially worldwide in recent weeks. The Omicron subvariant represented 10.7% of genetically analyzed viral samples worldwide for the week ending April 27, WHO data show. That was up sharply from the week ending April 6, when the subvariant accounted for 2.5% of samples worldwide.
'While still low numbers, this is a significant rise,' the WHO said, adding that there was a 'concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread.'
NB.1.8.1 isn't yet prevalent enough in the United States to be publicly tracked by the CDC. Another strain, LP.8.1, accounted for an estimated 73% of coronavirus specimens nationally for the two-week period ending Saturday.
Data suggest NB.1.8.1 does not cause more severe illness, 'but it is more transmissible, at least from what we're seeing around the world and also from lab experiments,' said Dr. Yvonne Maldonado, an infectious-disease expert at Stanford University.
In Taiwan, a top health official told reporters that an NB.1.8.1-fueled outbreak was 'continuing to rise rapidly, with a sustained increase in severe and fatal cases,' the Central News Agency reported, prompting a shortage of COVID testing kits. Health officials said a factor in Taiwan's surge was the lack of a major COVID wave over the winter, and forecast that the island's current spike may not peak for another four to six weeks.
NB.1.8.1 has seen increased prevalence in each of the three WHO regions that still consistently share genetic analysis of COVID samples — the Western Pacific (which includes East Asia, parts of Southeast Asia, and Australia); Europe; and the Americas.
The rate at which COVID tests are coming back positive in Los Angeles County has slightly increased over the past few weeks, although the overall positive rate remains low, at 3.5%, according to the county Department of Public Health. Coronavirus levels detected in the county's wastewater have increased by 6% in the last three weeks, but also remain relatively low and are about one-eighth of the peak in the summer of last year.
Although California experienced a mild winter season — a first of the COVID era — that followed a powerful summer spike that was the strongest in years.
Many experts and officials have touted available COVID vaccines as effective both in warding off infection and in lessening the severity of symptoms. However, the need for otherwise healthy individuals to roll up their sleeves has been a matter of debate.
In a video message Tuesday on X, Kennedy — a noted vaccine skeptic — said that he 'couldn't be more pleased to announce that, as of today, the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended immunization schedule.'
Experts said they could not recall a time when a political appointee circumvented a well-established process of making vaccine recommendations, which typically involves panels of scientists advising the FDA and CDC.
'It's kind of chilling,' Chin-Hong said. 'It's out of step with the system we've learned to trust and follow.'
In a statement to The Times, the L.A. County Department of Public Health urged Kennedy to listen to experts in the field — including from the CDC's Advisory Committee on Immunization Practices, which is scheduled to meet next month — 'before decreasing access to any vaccine.'
As of Thursday, the CDC still had the long-standing vaccine recommendations on its website: Everyone ages 6 months and older should get the most recent COVID-19 vaccine, officially known as the 2024-25 version, which was introduced in September. The CDC also recommends seniors ages 65 and up get a second vaccine dose six months after their first.
In a statement, the California Department of Public Health said that it supports the current expansive recommendation for COVID vaccines, and that it 'will continue to follow the federal conversation through this dynamic situation.'
'Staying up to date with COVID-19 vaccination can reduce the risk of disease, especially more severe cases that result in hospitalization or death,' the department added.
The Washington Post reported Wednesday that the CDC did not know of Kennedy's directive until he posted it, and officials have been 'scrambling to find out what it meant.'
Experts who spoke with The Times warned the practical effect of the edict — if it becomes official — could be far more costly vaccines for affected groups.
'If vaccines are not recommended by the CDC, insurance companies would NOT be required to cover the cost,' the L.A. County Department of Public Health said in a statement.
As a result, the vaccines may be less accessible to healthier people who still want them — perhaps because they live or work with elderly or other higher-risk people, they've had severe COVID illness before, or they want to protect themselves against the latest subvariant, the agency said.
If the FDA withholds a license for an updated COVID vaccination for younger, healthier adults, this group 'would not be able to receive it unless their provider chooses to give it 'off label,'' the county said.
When asked whether healthy pregnant women and healthy children can still get vaccinated at its pharmacies, Walgreens said its teams operate 'in full compliance with applicable laws.' CVS said its locations 'follow federal guidance regarding vaccine administration and are monitoring any changes that the government may make regarding vaccine eligibility.'
Kaiser Permanente Southern California said it was aware of potential changes, but noted no new formal guidance has yet been issued. As a result, Kaiser is continuing to follow existing guidance, which recommends the shots for everyone.
The L.A. County Department of Public Health said that as of Wednesday, 'pregnant women and healthy children can get vaccinated for COVID-19,' according to existing recommendations from an advisory panel and the CDC.
Chin-Hong noted there were 150 pediatric deaths in the U.S. from COVID-19 in a recent one-year period. That's in the same ballpark as the 231 pediatric flu deaths recorded this season, and federal health officials recommend everyone ages 6 months and older get an annual flu shot.
'Most people would agree that kids should be targeted for flu vaccines. It seems kind of weird to have COVID as an outlier in that respect,' Chin-Hong said.
In the video published this week, Makary said that 'most countries in the world have stopped recommending the vaccine for children.'
Maldonado, however, said the U.S. doesn't use other nations' standards to dictate vaccine recommendations. The U.S., for instance, recommends other types of vaccines that have a lower prevalence than COVID that people want to get, Maldonado said, such as the meningococcal vaccine for children to guard against a serious bacterial disease that can infect the brain and spinal cord and cause death within hours.
The effect of a recommendation also varies by country. Canada, for instance, recommends updated COVID vaccines for seniors and other people who meet certain criteria, such as if they're pregnant or are a healthcare worker. But the country's universal healthcare system still allows everyone ages 6 months and older to get an updated COVID vaccine.
Although it's true that children overall are at lower risk of developing severe COVID illness, those under 6 months of age 'have the same risk of complications as the 65-year-old-plus population in this country,' said Stanford's Maldonado, who also serves on the CDC's Advisory Committee on Immunization Practices.
Among children eligible for vaccination, COVID-associated hospitalization rates are highest for those ages 6 months to 4 years, according to the CDC.
'So are children going to be the highest risk group? No, they're not. But would you want to protect your child from a disease that could potentially put them in the hospital and get them on a ventilator? Yes, I would say that I would want to make that choice for myself. And why not allow the parent to make that choice?' Maldonado said.
The CDC says COVID vaccination during pregnancy builds antibodies that can help protect the baby; studies have also shown that vaccinated moms who breastfeed have protective antibodies in their milk, which could help protect their babies.
There have been an estimated 260,000 to 430,000 hospitalizations attributed to COVID since October, causing 'an enormous burden on the healthcare system,' Dr. Fiona Havers, a medical epidemiologist with the CDC, said at a recent public meeting. There have also been an estimated 30,000 to 50,000 COVID-19 deaths over the same time period.
'It is a major cause of morbidity and mortality, particularly in older adults, but it does affect other people, particularly those with underlying conditions, in younger age groups.'
COVID is also a major cause of pediatric hospitalizations, even among otherwise healthy children, she said.
'If there's a summer wave this year, we'll be seeing it in children being hospitalized with COVID as well,' she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
13 minutes ago
- CNBC
Hims to cut 4% of workforce amid ban on weight-loss drug copies
NEW YORK, May 30 (Reuters) - Telehealth platform Hims & Hers (HIMS.N), opens new tab will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy. A U.S. Food and Drug Administration ban on compounded copies of Wegovy, made by Novo Nordisk ( opens new tab, took effect on May 22. Hims shares have since dropped 14%. The company confirmed the job cuts in a statement on Friday. On Saturday, it said that the reductions were not related to the compounding ban. Hims did not provide details about the roles that were cut, but said they were implemented across teams. "These changes are focused on sharpening how we execute, without affecting our priorities or the specialties we're committed to," a company spokesperson said regarding the layoffs. Hims still plans to hire for roles related to its long-term growth strategy. The company recently announced an agreement with Novo to help patients access brand-name Wegovy. It plans to enter the market for low testosterone and menopause treatments and is looking at offerings to improve longevity and sleep. Bloomberg News reported the job cuts earlier on Friday. In 2022, the FDA declared a shortage of Wegovy, which has been shown to help patients lose around 15% of their body weight. That declaration allowed compounding pharmacies to produce the drug to meet demand. Hims began offering copies of Wegovy in 2024, often at far lower prices than the brand-name version. That boosted subscriptions to the Hims telehealth platform, with revenue up 111% on a yearly basis during the first quarter of 2025. Wegovy copies and similar GLP-1 weight-loss drugs accounted for $200 million of the company's $1.5 billion revenue in 2024. The FDA in February said Wegovy was no longer in shortage and ended the exception that allowed sale of mass compounded copies of the patented medication. Hims and its rivals have pivoted to what they say are customized copies of Wegovy that should not be subject to the FDA decision, featuring smaller doses or allowing for a more individualized plan for increasing dosage than offered by Novo. But analysts said that personalization strategy may not be enough to stave off new legal challenges from Novo. "It remains to be seen whether HIMS method of personalization (titration and dosage) is enough to meet the compounding clinical exemption need," said Jailendra Singh, a healthcare analyst at Truist.


Forbes
27 minutes ago
- Forbes
COVID-19 Disease Burden Remains High, Study Shows
A recent study has shown that COVID-19 remains a significant threat. Our public health response ... More needs to reflect this continued disease burden. Photographer: Graham Hughes/Bloomberg Researchers in Denmark conducted a large-scale evaluation of the disease burdens associated with COVID-19 and influenza. Their conclusion? COVID-19 has a greater impact than influenza, resulting in more hospitalizations and deaths. These findings, they note, emphasize the continued need for a strong public health response. To compare the disease burden of COVID-19 and influenza, the researchers evaluated data available from Danish health registries from May 16, 2022 to June 7, 2024. The results were published in The Lancet Infectious Diseases. A commentary about the findings was published in the same issue of the journal. During this period, the risk of hospitalization due to COVID-19 was approximately two times higher than the risk of hospitalization due to influenza. The risk of death was approximately three times higher. The researchers note that these increased risks were greater during the first year of the study period but still were evident during the second year. The risk of mortality, for example, was five times greater for COVID-19 during the first year of the study. That increased risk dropped during the second year, but COVID-19 still had a two and a half times greater risk of mortality than influenza. Infectious disease experts often cite the case fatality rate of an infectious agent as one measure of its disease burden. Simply, the CFR represents the proportion of people diagnosed with an infectious disease who die from the disease. Five years since the beginning of the COVID-19 pandemic, roughly 780 million confirmed cases of COVID-19 have been reported worldwide, resulting in over 7 million deaths, according to data provided by the World Health Organization. The ratio in the U.S. is similar. About 103 million cases and 1.22 million deaths have been reported. These numbers indicate a CFR of approximately 1%. This rate is significantly lower than the rates associated with other recent coronavirus outbreaks like SARS (CFR = 11%) and MERS (CFR = 34%). However, the CFR of COVID-19 far exceeds the CFR of seasonal influenza. The disease burden of COVID-19 certainly has dropped over the course of the pandemic. Various factors most likely have contributed to this change. Most people today possess some degree of natural or vaccine-induced immunity. As a result, rates of severe disease, hospitalization, and death should be lower. But the disease burden remains significant. We must continue our efforts to prevent new infections and develop effective treatments for infected individuals. In their article, Bager et al. note, 'These results highlight the continued need for attention and public health efforts to mitigate the impact of SARS-CoV-2.' In the accompanying commentary, Dr. Yan Xie, a researcher at the Washington University School of Medicine, noted that there exists, 'a profound disconnect between empirical evidence and public health policy, particularly in vaccine prioritisation strategies.' He added, 'Governments must prioritize robust surveillance and monitoring systems, data collection, analysis, and clear communication about the state of infectious threats, including COVID-19's ongoing impacts.' When asked to elaborate on these points, Dr. Xie commented, 'The disconnect arises primarily from the notion that COVID-19 has become less severe and in the eyes of many an inconsequential infection.' The empirical evidence, however, suggests otherwise. COVID-19 remains a significant public health problem. Yet, our efforts to address the disease are waning. In recent weeks, the Food and Drug Administration commissioner Dr. Martin A. Makary wrote that future formulations of the COVID-19 vaccine would need to undergo extensive clinical trials before being approved for use in healthy people between 6 months and 64 years and age. And Robert F. Kennedy Jr. announced that the COVID-19 vaccine would be removed from the CDC immunization schedule for healthy children and healthy pregnant women. These changes undoubtedly will reduce access to the vaccines and thus increase people's risk of becoming infected. COVID-19 has not gone away. We must remain vigilante and committed to addressing this ongoing threat. Now is not the time to relax our efforts. As Dr. Xie remarked, 'Aligning policies with reality is crucial to effectively protect public health. Wishful thinking is just that - wishful thinking.'


UPI
an hour ago
- UPI
FDA OKs new COVID-19 vaccine for 65 and older, others with conditions
A vial of the Moderna COVID-19 vaccine in the Meuhedet Clinic in Jerusalem on January 3, 2022. The FDA approved a new version of the vaccine on Friday. File photo by Debbie Hill/UPI | License Photo May 31 (UPI) -- The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened vaccine standards for the virus. The FDA announced Friday that mNEXSPIKE can be given to adults 65 and older and those 12 to 64 with at least one underlying condition that could put them at risk of severe infection. Recipients also must have been previously vaccinated for COVID-19. The company, headquartered in Cambridge, Mass., said Saturday it expects to have the vaccine available for the 2025-2026 respiratory virus season. Moderna also produces Spikevax for COVID-19, and mRESVIA for the respiratory syncytial virus, or RSV. "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," Stéphane Bancel, chief executive officer of Moderna, said. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." STAT reported the next-generation COVID-19 vaccine uses a refined target to generate antibodies against the SARS-CoV-2 virus. The dose is one-fifth the doage used in Spikevax, the current vaccine. Moderna conducted a randomized, observer-blind Phase 3 clinical trial of approximately 11,400 participants aged 12 years and older to test the mRNA-1283. The primary efficacy was to demonstrate the vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared with Spikevax, Moderna's updated COVID-19 vaccine approved on Sept. 6, 2024. The new vaccine showed a 9.3% higher relative vaccine efficacy than the mRNA-1273 in individuals aged 12 years and older. It was 13.5% better in adults aged 65 and older. In the Phase 3 trial, the most common side effects were injection site pain, fatigue, headache and myalgia. The company said there is a very small chance that mNEXSPIKE could cause a severe allergic reaction, usually within a few minutes to 1 hour after getting a dose of mNEXSPIKE. Myocarditis, which is inflammation of the heart muscle, and pericarditis, which is inflammation of the lining outside the heart, have occurred in some people who have received mRNA COVID-19 vaccines, Moderna said. Of those with problems, they are among males12 through 24. The FDA has asked Moderna to conduct post-marketing studies to continue to evaluate the safety and effectiveness of the product. This includes a study on the outcomes of pregnant people and their babies when the vaccine was administered during pregnancy. The study is to be submitted by the end of 2032. Pfizer was the first COVID-19 vaccine to receive emergency approval in December 2020 and Moderna was followed one week later. The first COVID-19 cases were reported in the United States in January 2020. The FDA first granted Pfizer-BioNTech full COVID-19 approval for those 12 and older in August 2021 and Moderna in January 2022. They remain available under emergency use authorization for children as young as 6 months. On Friday, the Centers for Disease Control and Prevention said children without underlying health conditions "may receive" a COVID-19 vaccine, contradicting a directive by Health and Human Services Secretary Robert F. Kennedy Jr. earlier in the week. The CDC updated the childhood immunization schedule published late Thursday. Kennedy, who said the agency would stop recommending the shots for healthy children, noted the guidelines would be changed. The new schedule also requires health insurance companies, Medicare and Medicaid plans to continue to cover the vaccines for children. COVID-19 shots during pregnancy are listed as "No Guidance/Not Applicable," where they were previously recommended for all pregnant adults. Earlier this month, the FDA approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay. The agency approved the vaccine only for people 65 and older and those 12 and older with at least one underlying condition at a higher risk of severe illness. This week, HHS notified Moderna that it was canceling contracts worth $766 million to develop, test and license vaccines for flu subtypes that could trigger future pandemics, including the dangerous H5N1 bird flu virus. The first COVID-19 case was reported in the United States on Jan. 20, 2020. About 23% of U.S. adults are estimated to be up to date with the vaccine, according to the CDC through April. For children 6 months and up to 18, it is an estimated 13.%, the CDC reported.